<DOC>
	<DOCNO>NCT01859819</DOCNO>
	<brief_summary>To safely reduce burden therapy child , adolescent young adult mature B-NHL reduce number intrathecal ( IT ) injections introduction IT Liposomal Cytarabine ( L-ARA-C , [ DepocytÂ® ] ) reduce dose anthracycline ( doxorubicin ) good risk patient addition rituximab FAB chemotherapy backbone ( Immunochemotherapy ) .</brief_summary>
	<brief_title>Treatment Advanced B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Newly diagnose mature Blineage ( CD20 positive ) Leukemia/Lymphoma 1 . Diffuse Large Cell Lymphoma ( NOT primary mediastinal Bcell lymphoma ) 2 . Burkitt 's Lymphoma 3 . High Grade Bcell LymphomaBurkitt 's like . BCell Anaplastic Large cell Ki 1 positive lymphoma , Primary Mediastinal BCell Lymphoma ( PMBL ) , BLymphoblastic lymphoma ineligible . No previous chemotherapy . Patients receive emergency irradiation and/or steroid therapy eligible ONLY start protocol therapy 72 hour start radiotherapy steroid . Bone marrow cerebrospinal fluid MUST obtain steroid give patient eligible study . Patients newly diagnose Group A ( low risk ) lymphoma . Patients Group B ( intermediate risk ) classify Murphy Stage III/IV diagnostic LDH &gt; 2 XULN patient primary mediastinal Bcell lymphoma ( PMBL ) . Patients receive steroid week prior diagnosis except state Section 4.1.4 protocol . No congenital acquire immune deficiency . These patient exclude due expect intense immunosuppression , increase risk opportunistic infection , high expect septic death rate subgroup patient propose therapy . No prior solid organ transplantation . Patients previous malignancy treat systemic chemotherapy alkylator anthracycline therapy . The latter group patient exclude due expected increase late effect ( eg . late cardiac toxicity , secondary malignancy , sterility , etc. ) . Patients know G6PD deficiency NOT ELIGIBLE Rasburicase therapy . Patients G6PD deficiency treat alkalinization , IV hydration po and/or IV allopurinol reduction phase ( COP ) . 4.2.6 Patients serious ( sepsis , pneumonia , etc.. ) proven suspect infection diagnosis exclude . 4.2.7 Pregnancy BreastFeeding : No information available regard human fetal teratogenic toxicity . Pregnancy test must obtain girl postmenarchal . Males female reproductive potential may participate unless agree use effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>31 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Lymphoma ( NOT primary mediastinal B-cell lymphoma )</keyword>
	<keyword>B-Cell -- -Burkitt 's like</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Liposomal ARA-C</keyword>
</DOC>